Read by QxMD icon Read

ovarian cancer cytoreduction

Linlin Wang, Fang Zhang, Jian-Ying Cui, Liang Chen, Yue-Ting Chen, Bo-Wen Liu
Carcinoma‑associated fibroblasts (CAFs) are the major components of mesenchymal cells in the inflammatory tumor microenvironment. They are involved in epithelial‑mesenchymal transition (EMT) and chemotherapy resistance by directly contacting with cancer cells or secretory cytokines. In the present study, we examined the role of CAFs in the induction of EMT in ovarian cancer. Primary ovarian cancer cells, CAFs and normal fibroblasts (NFs) were isolated from fresh cancer tissue and cultured for immunohistochemistry studies...
May 2018: Oncology Reports
Ramez N Eskander, James Kauderer, Krishnansu S Tewari, Robert S Mannel, Robert E Bristow, David M O'Malley, Stephen C Rubin, Gretchen E Glaser, Chad A Hamilton, Keiichi Fujiwara, Warner K Huh, Frederick Ueland, Jean-Marie Stephan, Robert A Burger
PURPOSE: We sought to determine the level of concordance among surgeons' assessment of residual disease (RD) and pre-treatment computed tomography (CT) findings among women who underwent optimal surgical cytoreduction for advanced stage ovarian cancer. METHODS: This is a post-trial ad hoc analysis of a phase 3 randomized clinical trial evaluating the impact of bevacizumab in primary and maintenance therapy for patients with advanced stage ovarian cancer following surgical cytoreduction...
March 14, 2018: Gynecologic Oncology
Stefano Uccella, Maria Cristina Mele, Lorena Quagliozzi, Emanuele Rinninella, Camilla Nero, Serena Cappuccio, Marco Cintoni, Antonio Gasbarrini, Giovanni Scambia, Anna Fagotti
OBJECTIVE: To investigate whether patients' altered body composition (measured with bioimpedentiometry), due to a poor nutritional status, predicts the incidence of no residual disease at primary debulking and the risk of complications in patients with newly-diagnosed advanced epithelial ovarian cancer (EOC). METHODS: Data regarding patients with newly-diagnosed stage IIIC-IV EOC undergoing elective nutritional assessment between December 2016 and March 2017, were prospectively collected...
March 14, 2018: Gynecologic Oncology
Alpaslan Kaban, Samet Topuz, Pınar Saip, Hamdullah Sözen, Yavuz Salihoğlu
OBJECTIVE: It is known that optimal or complete cytoreduction is the most important factor in patients with advanced ovarian cancer. The aim of this study was to examine the results of patients who did not undergo optimal cytoreduction and to examine subgroup analysis based on neoadjuvant chemotherapy. MATERIAL AND METHODS: Patients with advanced ovarian cancer and suboptimal surgery were retrospectively reviewed. RESULTS: A total of 99 patients with a median age of 59...
March 16, 2018: Journal of the Turkish German Gynecological Association
Marco Ceresoli, Apollonia Verrengia, Giulia Montori, Luisa Busci, Federico Coccolini, Luca Ansaloni, Luigi Frigerio
OBJECTIVE: Hyperthermic intraperitoneal chemotherapy (HIPEC) has been proposed as a treatment in ovarian cancer. A recently published RCT demonstrated that HIPEC prolongs disease-free survival (DFS) and overall survival (OS) in ovarian cancer. The aim of the study was to investigate oncologic results of cytoreductive surgery+HIPEC compared with cytoreductive surgery alone in advanced primary ovarian cancer with a particular attention to the pattern of recurrence. METHODS: This is a retrospective case control study with a propensity score (PS) matching of the patients...
March 12, 2018: Journal of Gynecologic Oncology
Giorgio Bogani, Elena Tagliabue, Mauro Signorelli, Antonino Ditto, Fabio Martinelli, Valentina Chiappa, Lavinia Mosca, Ilaria Sabatucci, Umberto Leone Roberti Maggiore, Domenica Lorusso, Francesco Raspagliesi
OBJECTIVE: To test the applicability of the Arbeitsgemeinschaft Gynäkologische Onkologie (AGO) and Memorial Sloan Kettering (MSK) criteria in predicting complete cytoreduction (CC) in patients undergoing secondary cytoreductive surgery (SCS) for recurrent ovarian cancer (ROC). METHODS: Data of consecutive patients undergoing SCS were reviewed. The Arbeitsgemeinschaft Gynäkologische Onkologie OVARian cancer study group (AGO-OVAR) and MSK criteria were retrospectively applied...
February 23, 2018: Journal of Gynecologic Oncology
John O Schorge, Amy J Bregar, John Durfee, Ross S Berkowitz
Joe V. Meigs was a visionary clinician and an early adopter of radical techniques in the surgical treatment of ovarian cancer. His 1934 textbook "Tumors of the Female Pelvic Organs", consolidated his approach to this "hopeless" disease, with pearls on diagnosis, outcomes, and even speculations about the benefits of minimally invasive surgery. Decades before adjuvant chemotherapy would prove of value, and in an era when sophisticated statistics were unheard of, he nonetheless tried to eke out what benefits he could using the methods available in his time...
March 7, 2018: Gynecologic Oncology
David Kudlowitz, Alejandro Velastegui, Fernanda Musa, Franco Muggia
PURPOSE: We report here on the tolerance of a carboplatin-'divided dose' paclitaxel (given on days 1 and 11) regimen in chemotherapy-naïve patients with resected and staged endometrial epithelial neoplasms deemed at high-risk of recurrence or early stage epithelial high-grade serous tubo-ovarian adenocarcinomas after risk-reducing surgery. More recently, we applied this regimen as neoadjuvant chemotherapy for advanced ovarian cancer presentations. METHODS: A retrospective chart review of patients receiving this day 1, 11 paclitaxel regimens in combination with carboplatin at AUC 6 every 3 weeks since 2004 was carried out by the second author with subsequent updates by the first and third authors...
March 7, 2018: Cancer Chemotherapy and Pharmacology
Lee Shyang Kyang, Sarah J Valle, Nayef A Alzahrani, David L Morris
Peritoneal metastasis (PM) following primary resection of colorectal cancer is common. The combined use of cytoreductive surgery and hyperthermic intraperitoneal chemotherapy has significantly improved the survival outcome of patients with colorectal PM (CRPM). Diagnosing and treating early PM is essential as its extent is correlated with poorer outcomes. There are two novel therapies - second-look surgery and synchronous hyperthermic intraperitoneal chemotherapy - that are proposed to prophylactically treat or intervene early in the disease process to reduce the incidence and adverse outcomes associated with PM...
March 6, 2018: ANZ Journal of Surgery
Mark B Bignell, Akash M Mehta, Sue Alves, Kandiah Chandrakumaran, Sanjeev P Dayal, Faheez Mohamed, Tom D Cecil, Brendan J Moran
AIM: Ovarian metastases from gastrointestinal tract malignancy have been considered an ominous finding with poor prognosis. The aim of this project was to determine the impact on survival, and potential cure, when cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC) are combined to treat peritoneal malignancy in women with Krukenberg tumours. METHOD: Retrospective analysis of prospectively collected data between January 2010 and July 2015...
March 4, 2018: Colorectal Disease: the Official Journal of the Association of Coloproctology of Great Britain and Ireland
Meng Qin, Ying Jin, Li Ma, Yan-Yan Zhang, Ling-Ya Pan
Objective: We aimed to performed a meta-analysis and systematic review on the role of neoadjuvant chemotherapy followed by interval debulking surgery (NACT-IDS) in advanced ovarian cancer (AOC) patients. Materials and Methods: We searched PubMed, EMBASE, and the Cochrane Library for relevant articles. All statistical analyses were performed in Review Manager 5.3.5. Results: In two randomized controlled trials (RCTs), there was no significant difference in overall survival (OS) (HR = 0...
February 2, 2018: Oncotarget
Víctor Lago, Santiago Domingo, Luis Matute, Pablo Padilla-Iserte, Marta Gurrea
In order to reach cytoreduction in advanced ovarian cancer, peritonectomy and diaphragmatic stripping are procedures required to remove the disease in the upper abdomen. Diaphragm involvement is estimated in up to 40% of cases. Nevertheless, in some of these patients, the tumour volume may constitute a limitation of the technique due to the association with abdominal wall involvement, bulky tumour at the Morrison's pouch or liver infiltration. Extensive upper abdominal procedures should represent a basic resource for the gynaecologic oncologist in order to reach an optimal cytoreduction...
2018: Ecancermedicalscience
Geoffroy Canlorbe, Cyril Touboul, Cyrus Chargari, Enrica Bentivegna, Amandine Maulard, Patricia Pautier, Catherine Genestie, Philippe Morice, Sébastien Gouy
AIM: To evaluate the influence on relapse-free survival (RFS) and overall survival (OS) of a transitory protective stoma (TPS) at the time of complete cytoreductive surgery for advanced-stage ovarian cancer. PATIENTS AND METHODS: From our Institution, we retrospectively selected patients from 2006 to 2011 with ovarian cancer with the following criteria: stage IIIB to IVA (pleural effusion) according to the International Federation of Gynaecology and Obstetrics classification; complete cytoreductive surgery (CC0 according to Sugarbaker's classification); and a low anterior resection...
March 2018: Anticancer Research
Davis T Weaver, Tiana J Raphel, Alexander Melamed, J Alejandro Rauh-Hain, John O Schorge, Amy B Knudsen, Pari V Pandharipande
OBJECTIVE: For patients with advanced stage epithelial ovarian cancer (EOC), substantial emphasis has been placed on diagnostic tests that can discern which of two treatment options - primary cytoreductive surgery (PCS) or neoadjuvant chemotherapy followed by interval cytoreductive surgery (NACT+ICS) - optimizes patient-level outcomes. Our goal was to project potential life expectancy (LE) gains that could be achieved by use of such a test. METHODS: We developed a microsimulation model to project LE for patients with stage IIIC EOC...
February 24, 2018: Gynecologic Oncology
Nicolae Bacalbasa, Irina Balescu, Cristian Balalau, Olivia Ionescu, Claudia Stoica
BACKGROUND/AIM: Diaphragmatic surgery in advanced-stage ovarian cancer has been considered since long time to increase the rates of postoperative complications. However, improvement of surgical techniques and perioperative management of these patients has lead in the last decade to a safe association of such procedures as part of debulking process. The aim of the current paper was to report our experience regarding the role of diaphragmatic resections as part of debulking surgery for advanced stage ovarian cancer...
March 2018: In Vivo
Nicolae Bacalbasa, Irina Balescu, Cristian Balalau, Olivia Ionescu, Claudia Stoica
Inguinal lymph node mass as the first sign in patients with ovarian cancer represents a rare situation, with only few cases being reported so far. We present the case of a 46-year-old patient who presented for the apparition of bilateral inguinal tumoral masses in the absence of any other pathological signs. The biopsy revealed the presence of an adenocarcinoma with probable genital origin; however, neither the gynaecological examination nor the computed tomography demonstrated the presence of any suspect lesion...
March 2018: In Vivo
Antoni Llueca, Anna Serra, Isabel Rivadulla, Luis Gomez, Javier Escrig
BACKGROUND: The peritoneal carcinomatosis index (PCI) can be used to quantify the tumor burden in patients with advanced ovarian cancer. The aim of the present study was to establish a predictive model for suboptimal cytoreductive surgery (SCS) (residual tumor of > 1 cm) using preoperative and intraoperative determination of the PCI. METHODS: In total, 110 consecutive patients treated for advanced ovarian cancer during a 4-year period in our institution were assessed...
February 23, 2018: World Journal of Surgical Oncology
Dong Hoon Suh, Miseon Kim, Kyung Hun Lee, Keun Yong Eom, Maj Kamille Kjeldsen, Mansoor Raza Mirza, Jae Weon Kim
In 2017, 10 topics were selected as major clinical research advances in gynecologic oncology. For cervical cancer, efficacy and safety analysis results of a 9-valent human papillomavirus (HPV) vaccine and long-term impact of reduced dose of quadrivalent vaccine were updated. Brief introduction of KEYNOTE trials of pembrolizumab, a monoclonal antibody that blocks the interaction between programmed death (PD)-1 and its ligands, PD-L1 and PD-L2, followed. Tailored surveillance programs for gynecologic cancer related with Lynch syndrome and update on sentinel lymph node mapping were reviewed for uterine corpus cancer...
March 2018: Journal of Gynecologic Oncology
Andrew Phillips, Sudha Sundar, Kavita Singh, James Nevin, Ahmed Elattar, Sean Kehoe, Janos Balega
OBJECTIVES: To assess the impact of 5 or more cycles of neoadjuvant chemotherapy (NACT) and cytoreductive outcomes on overall survival (OS) in patients undergoing interval debulking surgery (IDS) for advanced ovarian cancer. METHODS: A retrospective review of patients receiving NACT followed by IDS between 2007 and 2017. Patients were analysed according to number of NACT cycles received: group 1 consisted of patients receiving ≤4 cycles and group 2 consisted of those receiving ≥5 cycles...
January 31, 2018: European Journal of Surgical Oncology
Lesley B Conrad, Haitham Awdeh, Stefany Acosta-Torres, Steven A Conrad, April A Bailey, David S Miller, Jayanthi S Lea
BACKGROUND AND OBJECTIVES: Age and frailty have been correlated with poor clinical outcomes in cancer. Core muscle index (CMI) and nutritional status are integral in assessing frailty. We explored the effect of pre-operative serum albumin and body composition on clinical outcomes in patients with epithelial ovarian cancer (EOC). METHODS: We identified stage III-IV EOC patients undergoing primary cytoreductive surgery from 2007 to 2015. Data were abstracted from medical records...
February 6, 2018: Journal of Surgical Oncology
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"